GC511B / AstraZeneca, Gracell - LARVOL DELTA

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov) - P1 | N=55 | Recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2025 ➔ Mar 2026

Enrollment open • First-in-human • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

A Phase 1, First-in-Human, Investigator-Initiated, Open-label Study to Assess the Safety, Feasibility, Cytokinetics, and Preliminary Antitumor Activity of GC511B in Adult Subjects with DLL3+ Relapsed/Refractory Small Cell Lung Cancer (ChiCTR) - P1 | N=100 | Not yet recruiting | Sponsor: CancerCancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences Hospital

New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov) - P1 | N=55 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

First-in-human • New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor